OTCMKTS:HBPCFHelix Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Helix Biopharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.45 -0.03 (-5.94 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.45Now: $0.45▼$0.4550-Day Range$0.47MA: $0.69▼$0.8952-Week Range$0.21Now: $0.45▼$1.15Volume500 shsAverage Volume628 shsMarket Capitalization$59.37 millionP/E RatioN/ADividend YieldN/ABeta-0.13 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. The company is developing L-DOS47 for the treatment of non-squamous small cell lung cancer, as well as for colon, pancreas, and breast cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. The company has collaboration agreement with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. Helix BioPharma Corp. is headquartered in Richmond Hill, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Helix Biopharma. Previous Next 2.3 Community Rank Outperform VotesHelix Biopharma has received 44 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHelix Biopharma has received 52 “underperform” votes. (Add your “underperform” vote.)Community SentimentHelix Biopharma has received 54.17% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Helix Biopharma and other stocks. Vote “Outperform” if you believe HBPCF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HBPCF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHelix Biopharma does not currently pay a dividend.Dividend GrowthHelix Biopharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Helix Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Helix Biopharma is held by insiders. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Helix Biopharma is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Helix Biopharma is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HBPCF Previous Symbol CUSIPN/A CIKN/A Webwww.helixbiopharma.com Phone905-841-2300Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-22.33Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-5,680,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-447.54%Miscellaneous Employees22 Outstanding Shares132,933,000Market Cap$59.37 million Next Earnings Date7/14/2020 (Estimated) OptionableNot Optionable OTC:HBPCF Rates by TradingView Receive HBPCF News and Ratings via Email Sign-up to receive the latest news and ratings for HBPCF and its competitors with MarketBeat's FREE daily newsletter. Helix Biopharma (OTCMKTS:HBPCF) Frequently Asked Questions How has Helix Biopharma's stock been impacted by COVID-19 (Coronavirus)? Helix Biopharma's stock was trading at $0.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HBPCF stock has decreased by 54.0% and is now trading at $0.4466. View which stocks have been most impacted by Coronavirus. When is Helix Biopharma's next earnings date? Helix Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, July 14th 2020. View our earnings forecast for Helix Biopharma. Has Helix Biopharma been receiving favorable news coverage? Headlines about HBPCF stock have trended negative on Friday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Helix Biopharma earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Helix Biopharma. Who are some of Helix Biopharma's key competitors? Some companies that are related to Helix Biopharma include Verastem (VSTM), REDHILL BIOPHAR/S (RDHL), Lannett (LCI), Five Prime Therapeutics (FPRX), Fortress Biotech (FBIO), TAIWAN LIPOSOME/S (TLC), Selecta Biosciences (SELB), CymaBay Therapeutics (CBAY), Paratek Pharmaceuticals (PRTK), Verrica Pharmaceuticals (VRCA), Hookipa Pharma (HOOK), Agile Therapeutics (AGRX), Marinus Pharmaceuticals (MRNS), Aduro BioTech (ADRO) and Kalvista Pharmaceuticals (KALV). View all competitors. Who are Helix Biopharma's key executives? Helix Biopharma's management team includes the following people: Dr. Heman Chao, CEO, Chief Scientific Officer, Member of Scientific & Strategic Advisory Board and Director (Age 56)Mr. Photios Michalargias, CFO & Corp. Sec. (Age 56)Mr. Pawel Wisniewski, Chief Exec. Officer of PolandDr. Trevor Seaton M.D., FRCP(C), Vice Chairman of Medical Advisory Board What is Helix Biopharma's stock symbol? Helix Biopharma trades on the OTCMKTS under the ticker symbol "HBPCF." How do I buy shares of Helix Biopharma? Shares of HBPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Helix Biopharma's stock price today? One share of HBPCF stock can currently be purchased for approximately $0.45. How big of a company is Helix Biopharma? Helix Biopharma has a market capitalization of $59.37 million. Helix Biopharma employs 22 workers across the globe. What is Helix Biopharma's official website? The official website for Helix Biopharma is www.helixbiopharma.com. How can I contact Helix Biopharma? Helix Biopharma's mailing address is 9120 Leslie Street Suite 205, Richmond Hill A6, L4B3J9. The company can be reached via phone at 905-841-2300 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
